Overhauling Compliance and GMPs

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-04-02-2003, Volume 27, Issue 4

FDA's newly launched risk-based approach to GMP regulation spurs signficant changes in the agency's approach to inspection processes, postapproval changes, and 21 CFR Part 11 enforcement.

Related Content:

Regulatory/GMP ComplianceQuality SystemsRegulatory WatchPharmaceutical Technology-04-02-2003
The European Commission Approves Severe Alopecia Areata Treatment
Continuous Manufacturing is Here to Stay (PDA/FDA Joint Regulatory Conference 2023)
EC Approves Fixed-Dose Oral Combination Treatment for AML